SEOM clinical guideline for the management of cutaneous melanoma (2020)

Melanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of these patients. The diagnosis must be histological and...

Descripción completa

Detalles Bibliográficos
Autores: Majem, M, Manzano, JL, Marquez-Rodas, I, Mujika, K, Munoz-Couselo, E, Perez-Ruiz, E, de la Cruz-Merino, L, Espinosa, E, Gonzalez-Cao, M, Berrocal, A
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p4926
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4926
https://ddd.uab.cat/record/269846
Access Level:acceso abierto
Palabra clave:Melanoma
Adjuvant treatment metastatic treatment
Staging
id ES_5ade398fc735c305a81e9958f110bf2d
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p4926
network_acronym_str ES
network_name_str España
repository_id_str
spelling SEOM clinical guideline for the management of cutaneous melanoma (2020)Majem, MManzano, JLMarquez-Rodas, IMujika, KMunoz-Couselo, EPerez-Ruiz, Ede la Cruz-Merino, LEspinosa, EGonzalez-Cao, MBerrocal, AMelanomaAdjuvant treatment metastatic treatmentStagingMelanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of these patients. The diagnosis must be histological and determination of BRAF status has to be performed in patients with stage >= III. Stage I-III resectable melanomas will be treated surgically. In patients with stage III melanoma, adjuvant treatment with immunotherapy or targeted therapy is also recommended. Patients with unresectable or metastatic melanoma will receive treatment with immunotherapy or targeted therapy, the optimal sequence of these treatments remains unclear. Brain metastases require a separate consideration, since, in addition to systemic treatment, they may require local treatment. Patients must be followed up closely to receive or change treatment as soon as their previous clinical condition changes, since multiple therapeutic options are available.SPRINGER INTERNATIONAL PUBLISHING AG2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4926https://ddd.uab.cat/record/269846Clinical & Translational OncologyISSN: 1699048XISSNe: 16993055reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p49262026-06-14T12:41:47Z
dc.title.none.fl_str_mv SEOM clinical guideline for the management of cutaneous melanoma (2020)
title SEOM clinical guideline for the management of cutaneous melanoma (2020)
spellingShingle SEOM clinical guideline for the management of cutaneous melanoma (2020)
Majem, M
Melanoma
Adjuvant treatment metastatic treatment
Staging
title_short SEOM clinical guideline for the management of cutaneous melanoma (2020)
title_full SEOM clinical guideline for the management of cutaneous melanoma (2020)
title_fullStr SEOM clinical guideline for the management of cutaneous melanoma (2020)
title_full_unstemmed SEOM clinical guideline for the management of cutaneous melanoma (2020)
title_sort SEOM clinical guideline for the management of cutaneous melanoma (2020)
dc.creator.none.fl_str_mv Majem, M
Manzano, JL
Marquez-Rodas, I
Mujika, K
Munoz-Couselo, E
Perez-Ruiz, E
de la Cruz-Merino, L
Espinosa, E
Gonzalez-Cao, M
Berrocal, A
author Majem, M
author_facet Majem, M
Manzano, JL
Marquez-Rodas, I
Mujika, K
Munoz-Couselo, E
Perez-Ruiz, E
de la Cruz-Merino, L
Espinosa, E
Gonzalez-Cao, M
Berrocal, A
author_role author
author2 Manzano, JL
Marquez-Rodas, I
Mujika, K
Munoz-Couselo, E
Perez-Ruiz, E
de la Cruz-Merino, L
Espinosa, E
Gonzalez-Cao, M
Berrocal, A
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Melanoma
Adjuvant treatment metastatic treatment
Staging
topic Melanoma
Adjuvant treatment metastatic treatment
Staging
description Melanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of these patients. The diagnosis must be histological and determination of BRAF status has to be performed in patients with stage >= III. Stage I-III resectable melanomas will be treated surgically. In patients with stage III melanoma, adjuvant treatment with immunotherapy or targeted therapy is also recommended. Patients with unresectable or metastatic melanoma will receive treatment with immunotherapy or targeted therapy, the optimal sequence of these treatments remains unclear. Brain metastases require a separate consideration, since, in addition to systemic treatment, they may require local treatment. Patients must be followed up closely to receive or change treatment as soon as their previous clinical condition changes, since multiple therapeutic options are available.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4926
https://ddd.uab.cat/record/269846
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4926
https://ddd.uab.cat/record/269846
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv SPRINGER INTERNATIONAL PUBLISHING AG
publisher.none.fl_str_mv SPRINGER INTERNATIONAL PUBLISHING AG
dc.source.none.fl_str_mv Clinical & Translational Oncology
ISSN: 1699048X
ISSNe: 16993055
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869408751891513344
score 15,811543

Similares en LA Referencia